about
Pleiotropic effects of statins in the diseases of the liverInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionHepatitis C virus relies on lipoproteins for its life cycleSignificance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaLiver pathology of hepatitis C, beyond grading and staging of the diseaseChronic hepatitis C: This and the new era of treatmentGenetic, metabolic and environmental factors involved in the development of liver cirrhosis in MexicoEpidemiology of hepatitis C virus in IranChronic hepatitis C virus infection and lipoprotein metabolismThe yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNAFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CHepatitis C among healthcare personnel: secondary data analyses of costs and trends for hepatitis C infections with occupational causesEstimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3΄ variants.Hepatitis C infection in Egypt: prevalence, impact and management strategies.Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.Impact of Virtual Touch Quantification in Acoustic Radiation Force Impulse for Skeletal Muscle Mass Loss in Chronic Liver DiseasesSystematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit.Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent EraDuplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C PatientsLong-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.Exposure to hepatitis C virus in homeless men in Central Brazil: a cross-sectional study.Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virusSpontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases.New prospects for the treatment and prevention of hepatitis C in children.Distribution of Hepatitis C Virus Genotypes in Bahrain.The corrected donor age for hepatitis C virus-infected liver transplant recipients.Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States.Up-regulation of Plasma Hexosylceramide (d18: 1/18: 1) Contributes to Genotype 2 Virus Replication in Chronic Hepatitis C: A 20-Year Cohort StudyDisparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureRelationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patientsTreatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient PopulationSimeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.
P2860
Q26741176-061F26CD-ACE1-4090-B7EB-2FF0AD5F3D41Q26746563-7FFAE1E4-587B-4C9B-8C08-8916BFB3DF22Q26766119-6E82C94C-DEE5-4AC5-AA21-D29BA9B2896BQ26773251-79F3209B-103A-42DD-89D9-ED9200BE380EQ26773294-4F3D00AB-30F8-4800-BCF8-45B55C14EA34Q26775011-733F852B-19CF-4892-A910-F2D6E4B070B6Q26778035-2175E819-705C-42AD-8FD7-2211D0F586F3Q26781996-EAFBFBEA-6774-43A4-9D21-C3E2F5F591BBQ26784234-775F9EF9-EA22-4639-97F3-488D6F1052F7Q26800446-30FEA5E1-AAC3-43C1-84B5-8F20CE9CF01EQ28079826-C5661BCE-436C-4F83-9084-DDC0BF275947Q30235178-20CCBD95-F873-48C2-BC0E-B6CAF4FA5740Q31146258-07A83D61-9B8F-4FCA-812B-1BE0907CAE3AQ33629597-A98A14CE-4912-4AF9-95FB-E861ED383A36Q33636039-B9811CBE-2038-4CC9-AF90-B4E1A009E1C2Q33713718-5F868473-D7F0-42BF-B958-93126F18A76AQ33765497-22F234B8-4A2C-4864-B97C-07CBD74D5A5BQ33852130-2B19F74A-C232-421D-8A1D-D2A80F8A34E0Q34522481-25C7E7E0-5623-478F-81C8-F8176B8A2138Q35958590-87F089CF-371E-40A4-8C36-E2C2152F4B6CQ36133794-DBD3AF1B-9099-4FCD-8F93-3E01B1917422Q36184217-29D45D11-7640-4A98-98C0-D1AA4F07C358Q36193232-154E16D0-26F7-4B35-A7EE-AD7ED11A8A6FQ36253099-405A3E91-AFCC-4DAA-B6C8-EA05D16441C8Q36327172-774D91DD-3419-49AB-B8AA-89BF848514B3Q36403347-AE723F2D-F20C-4EEE-A310-7BD91DA70270Q36608054-470F5B06-EF95-4238-B31D-8A8EDEF06ACBQ36639886-975A2512-A9B9-4616-82BF-F4D629271AA4Q36734395-172CB7E3-BBCD-4E57-814C-29C794A132C8Q36988702-97AB3A1D-1DF0-49F6-96EB-0EFF2D18E92BQ37003642-5BF712D5-3B58-48C1-8BD7-309996E74B64Q37018340-8399001B-56B3-4BDE-BB3A-22D2FA291FEFQ37050953-DD613E98-BEFA-4443-B804-C7874DB0B1D7Q37135584-CA88B501-F37C-4C57-AEBE-7E29B29B2ABEQ37230823-3F13EAAE-FAA9-4851-9175-4C5A4000F61AQ37441421-BD456842-0315-4E5D-A71F-11466ECE27F4Q37631758-F051C46D-29C4-4170-AFD6-F185EB4081CDQ37646759-65F7F9BE-3D4E-421B-90A5-72412F0BCAF4Q38376454-930D1983-E20D-42C3-AE02-07817CCB2F6BQ38459012-5B64D1C3-E4F5-421B-8F3B-89BD79F16BF2
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Natural history of hepatitis C
@ast
Natural history of hepatitis C
@en
Natural history of hepatitis C
@nl
type
label
Natural history of hepatitis C
@ast
Natural history of hepatitis C
@en
Natural history of hepatitis C
@nl
prefLabel
Natural history of hepatitis C
@ast
Natural history of hepatitis C
@en
Natural history of hepatitis C
@nl
P3181
P1476
Natural history of hepatitis C
@en
P2093
Geoffrey Dusheiko
Rachel H. Westbrook
P304
P3181
P356
10.1016/J.JHEP.2014.07.012
P407
P433
P577
2014-11-01T00:00:00Z